Agilent Buys Proscia for Up to $270M

Laboratory technology company Agilent is acquiring digital pathology developer Proscia in a transaction worth up to $270 million, extending its reach from lab hardware into image-management and AI software.

What happened

Agilent agreed to purchase Proscia for $240 million in cash with up to $30 million of additional performance-based payments. Proscia develops software for digitising, organising, viewing and analysing pathology slides, including workflows that can incorporate AI applications. The companies already had a distribution relationship dating from 2022. Proscia reported more than $18 million in revenue during the preceding 12 months. Closing is expected in Agilent's early fiscal 2027, subject to required conditions. The agreement is not yet a completed acquisition, and the additional $30 million is contingent rather than guaranteed.

Why it matters

Pathology is still shifting from viewing glass slides through microscopes toward high-resolution digital images that can be shared, analysed and integrated with laboratory information systems. Software can help laboratories manage large image datasets, support remote collaboration and deploy computational tools. Agilent gains control of an established platform that complements instruments and other laboratory services it already sells.

The bigger picture

Medical diagnostics increasingly depend on integrated hardware, imaging data, workflow software and clinically validated algorithms. Acquisitions can help established suppliers assemble that stack more quickly. The clinical value of AI-assisted pathology will still depend on regulatory requirements, evidence of diagnostic accuracy and whether the technology improves patient care without adding new errors.